{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59","upperLimit":"92","value":"81"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"The percentage of participants alive and without disease progression at 2 years. Disease progression was judged through clinical impression and MRI imaging.","dispersionType":"95% Confidence Interval","groups":[{"description":"Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy\n\nHigh-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide","id":"OG000","title":"High-dose Chemotherapy With Autologous Stem Cell Transplant"}],"paramType":"NUMBER","populationDescription":"The participant that was lost to follow-up was not available for analysis.","reportingStatus":"POSTED","timeFrame":"2 years","title":"2-year Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}